CCL2 and neoplasm: In vivo studies applying the 4T1-BALB/c BC mouse model demonstrated that the inhibition of TGF-β causes a significant reduction in the levels of CCL2 expression in the primary tumor site, which correlates with lower levels of lung metastases14.